Ionis Pharmaceuticals, Inc. (IONS)

Capital Fund Management S.A. lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 46.2% in the second quarter, according to the company in its most recent Form 13F filing with the SE...

American Century Companies Inc. lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 304.9% during the undefined quarter, according to the company in its most recent filing with the SEC. ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganers...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-two research firms that are covering the stock, Marketbeat Ratings r...

Exploring Tweedy Browne (Trades, Portfolio)'s Recent 13F Filing and Investment Adjustments Tweedy Browne (Trades, Portfolio) recently submitted its 13F filing...

Ionis Pharmaceuticals, Inc. ( IONS ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants A...

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CN...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP...

Ionis Pharmaceuticals, Inc. ( IONS ) Stifel 2025 Healthcare Conference November 13, 2025 8:00 AM EST Company Participants Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Elizabeth L....